UnitedHealth Group Incorporated (NYSE:UNH) recorded a trading volume of 1.89 million shares, below its 90-day volume average of 2.87 million shares. The stock kicked off the session at $210.46 and later approached $209.9 with a change of -0.58%.UnitedHealth Group Incorporated (UNH) Analyst Opinion
UnitedHealth Group Incorporated has a consensus buy rating from 22 Wall Street analysts, and the number of shares currently sold short amount to at least 0.8% of shares outstanding. The stock spiked 3.27% last month and is up 31.15 this year. Wall Street is only getting more bullish on the stock, with 22 of analysts who cover UNH having a buy-equivalent rating. Analysts have placed a $229.65 price target on UnitedHealth Group Incorporated, suggesting a 9.41% gain from recent close. It’s currently trading about -1.88% below its 52-week high.UnitedHealth Group Incorporated Earnings Surprise
UnitedHealth Group Incorporated (UNH) surprised the stock market in its last reported earnings when it earned $2.66 a piece versus the consensus-estimated $2.56. Its revenue totaled $50.37 billion up 0.63% from the previous quarter.UnitedHealth Group Incorporated (NYSE:UNH) Intraday View
This stock (UNH) is ahead of its 52-week low with 41.29%. Its last month’s stock price volatility remained 1.16% which for the week stands at 1.35%. The share price has moved backward from its 20 days moving average, trading at a distance of -0.25% and stays 3.76% away from its 50 days moving average. Over the last five days, shares have faced -0.55% losses and now is up 14.07% since hitting its 200-day moving average of $191.42. UnitedHealth Group Incorporated (UNH) has made its way to a 12-month gain of 39.22%.
Turning to CytomX Therapeutics, Inc. (NASDAQ:CTMX), its shares were trading at $20.31 a gain of $0.05, on the trading floor. The stock, after opening at $20.11, touched a high of $20.4999 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. CytomX Therapeutics, Inc. has 3 buy ratings, 1 holds and 0 sells even after the stock tumbled -17.68% from its high of $24.67 to a $738.88 million market value through last close.CytomX Therapeutics, Inc. (CTMX) Consensus Price Target
The company’s consensus rating on Reuter’s scale improved from 1.67 to 1.71 during a month. Analysts set a 12-month price target of $35 a share. The target implies a 72.33% spike from where the shares are currently trading. Also, the current price highlights a discount of 116.64% to analysts’ high consensus price target.CytomX Therapeutics, Inc. (NASDAQ:CTMX) Intraday Trading
The counter witnessed a trading volume of 0.2 million shares versus an average volume of 0.36 million shares during last trading session. Its last month’s stock price volatility remained 4.99% which for the week approaches 4.01%. The lowest price the stock reached in the last trading day was $19.98 and compares with the $10.03 52-week low. The stock recovered 102.49% since its low point and has performed 84.8% year-to-date.